Epitomee Medical Ltd. is a medical device company focused on developing and commercializing innovative ingestible therapeutic devices. Its core technology centers on swallowable capsules engineered to deploy targeted therapies along specific regions of the gastrointestinal tract. These devices are designed to address some of today’s most prevalent chronic health conditions, including weight management and metabolic disorders, by enabling mechanosensory stimulation, precise drug delivery, and absorption management.

The company’s platform allows for self-ingestion, with each device intended to activate and function transiently within the digestive tract before being naturally evacuated. Epitomee Medical Ltd. is notable for its adaptability, as the function, duration, and location of its therapies can be tailored to various medical needs. In addition to direct product development, Epitomee collaborates with industry leaders to bring new therapeutic applications to market, expanding the reach and impact of its technology within the healthcare sector. Through these pioneering solutions, Epitomee Medical plays a significant role in advancing non-invasive treatments and broadening the accessibility of chronic disease management options.